(TMO) Thermo Fisher Scientific - Overview

Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NYSE (USA) | Market Cap: 184.365m USD | Total Return: 10.8% in 12m

Reagents, Instruments, Consumables, Diagnostics, Instruments

Total Rating 50

Safety 94

Buy Signal -0.21

Diagnostics & Research
Industry Rotation: -3.6

Market Cap: 184B
Avg Turnover: 858M USD

ATR: 2.90%
Peers RS (IBD): 51.7

Risk 5d forecast

Volatility24.3%

Rel. Tail Risk-6.48%

Reward TTM

Sharpe Ratio0.32

Alpha-10.62

Character TTM

Beta0.735

Beta Downside0.474

Drawdowns 3y

Max DD37.28%

CAGR/Max DD-0.14

EPS (Earnings per Share)

EPS CAGR: -47.58%
EPS Trend: -36.3%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: 0.88%
Rev. Trend: 4.2%

Last SUE: 3.38
Qual. Beats: 4

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: TMO Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) operates four core segments: Life Sciences Solutions, delivering reagents, instruments and consumables for drug discovery, vaccine production and disease diagnostics; Analytical Instruments, supplying hardware, software and services to pharma, biotech, academia and industrial labs; Specialty Diagnostics, offering immunodiagnostic kits, microbiology media, transplant typing and related consumables; and Laboratory Products & Biopharma Services, which provides a broad portfolio of lab supplies and contract manufacturing through brands such as Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

In its most recent fiscal year (2023), Thermo Fisher generated $46.2 billion in revenue-a 10 % year-over-year increase-driven largely by strong demand for COVID-19 testing supplies and expanding biopharma outsourcing. Adjusted earnings per share rose to $9.10, and the company posted an operating margin of roughly 15 %, underscoring its ability to translate top-line growth into profitability.

Key sector catalysts include accelerating global biotech R&D spend (projected to exceed $600 billion by 2026), an aging population that fuels demand for clinical diagnostics, and sustained government investment in vaccine and therapeutic manufacturing capacity. Thermo Fisher’s 2021 acquisition of contract research organization PPD, together with its ongoing integration of specialty-diagnostic assets, positions it to capture a larger share of the growing outsourced-services market.

For a deeper quantitative look, you might explore Thermo Fisher’s valuation metrics on ValueRay.

Headlines to Watch Out For

Biopharma services demand drives revenue growth
Research and development spending impacts instrument sales
Diagnostic product innovation expands market share
Global healthcare spending influences segment performance

Piotroski VR‑10 (Strict) 6.5

Net Income: 6.71b TTM > 0 and > 6% of Revenue
FCF/TA: 0.06 > 0.02 and ΔFCF/TA -1.76 > 1.0
NWC/Revenue: 30.34% < 20% (prev 20.53%; Δ 9.80% < -1%)
CFO/TA 0.07 > 3% & CFO 7.82b > Net Income 6.71b
Net Debt (31.00b) to EBITDA (11.48b): 2.70 < 3
Current Ratio: 1.89 > 1.5 & < 3
Outstanding Shares: last quarter (377.0m) vs 12m ago -1.57% < -2%
Gross Margin: 39.46% > 18% (prev 0.41%; Δ 3.91k% > 0.5%)
Asset Turnover: 42.91% > 50% (prev 44.06%; Δ -1.15% > 0%)
Interest Coverage Ratio: 6.13 > 6 (EBITDA TTM 11.48b / Interest Expense TTM 1.42b)

Altman Z'' 4.17

A: 0.12 (Total Current Assets 28.71b - Total Current Liabilities 15.19b) / Total Assets 110.34b
B: 0.54 (Retained Earnings 59.16b / Total Assets 110.34b)
C: 0.08 (EBIT TTM 8.70b / Avg Total Assets 103.83b)
D: 1.01 (Book Value of Equity 57.15b / Total Liabilities 56.81b)
Altman-Z'' Score: 4.17 = AA

Beneish M -2.97

DSRI: 1.06 (Receivables 10.57b/9.63b, Revenue 44.56b/42.88b)
GMI: 1.03 (GM 39.46% / 40.51%)
AQI: 0.95 (AQ_t 0.63 / AQ_t-1 0.66)
SGI: 1.04 (Revenue 44.56b / 42.88b)
TATA: -0.01 (NI 6.71b - CFO 7.82b) / TA 110.34b)
Beneish M-Score: -2.97 (Cap -4..+1) = A

What is the price of TMO shares? As of April 13, 2026, the stock is trading at USD 496.11 with a total of 1,308,732 shares traded.
Over the past week, the price has changed by +1.62%, over one month by +4.35%, over three months by -19.31% and over the past year by +10.82%.

Is TMO a buy, sell or hold? Thermo Fisher Scientific has received a consensus analysts rating of 4.39. Therefore, it is recommended to buy TMO.

StrongBuy: 18
Buy: 7
Hold: 6
Sell: 0
StrongSell: 0

What are the forecasts/targets for the TMO price?

Analysts Target Price	658.4	32.7%

Thermo Fisher Scientific (TMO) - Fundamental Data Overview as of 12 April 2026

P/E Trailing = 27.9341
P/E Forward = 20.202
P/S = 4.1378
P/B = 3.4823
P/EG = 1.8532
Revenue TTM = 44.56b USD
EBIT TTM = 8.70b USD
EBITDA TTM = 11.48b USD
Long Term Debt = 35.85b USD (from longTermDebt, last quarter)
Short Term Debt = 3.81b USD (from shortTermDebt, last quarter)
Debt = 40.85b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 31.00b USD (from netDebt column, last quarter)
Enterprise Value = 215.37b USD (184.37b + Debt 40.85b - CCE 9.85b)
Interest Coverage Ratio = 6.13 (Ebit TTM 8.70b / Interest Expense TTM 1.42b)
EV/FCF = 34.22x (Enterprise Value 215.37b / FCF TTM 6.29b)
FCF Yield = 2.92% (FCF TTM 6.29b / Enterprise Value 215.37b)
FCF Margin = 14.12% (FCF TTM 6.29b / Revenue TTM 44.56b)
Net Margin = 15.07% (Net Income TTM 6.71b / Revenue TTM 44.56b)
Gross Margin = 39.46% ((Revenue TTM 44.56b - Cost of Revenue TTM 26.98b) / Revenue TTM)
Gross Margin QoQ = 37.95% (prev 41.83%)
Tobins Q-Ratio = 1.95 (Enterprise Value 215.37b / Total Assets 110.34b)
Interest Expense / Debt = 0.89% (Interest Expense 365.0m / Debt 40.85b)
Taxrate = 7.21% (153.0m / 2.12b)
NOPAT = 8.07b (EBIT 8.70b * (1 - 7.21%))
Current Ratio = 1.89 (Total Current Assets 28.71b / Total Current Liabilities 15.19b)
Debt / Equity = 0.76 (Debt 40.85b / totalStockholderEquity, last quarter 53.41b)
Debt / EBITDA = 2.70 (Net Debt 31.00b / EBITDA 11.48b)
Debt / FCF = 4.93 (Net Debt 31.00b / FCF TTM 6.29b)
Total Stockholder Equity = 51.08b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.47% (Net Income 6.71b / Total Assets 110.34b)
RoE = 13.15% (Net Income TTM 6.71b / Total Stockholder Equity 51.08b)
RoCE = 10.01% (EBIT 8.70b / Capital Employed (Equity 51.08b + L.T.Debt 35.85b))
RoIC = 9.26% (NOPAT 8.07b / Invested Capital 87.20b)
WACC = 7.17% (E(184.37b)/V(225.22b) * Re(8.57%) + D(40.85b)/V(225.22b) * Rd(0.89%) * (1-Tc(0.07)))
Discount Rate = 8.57% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.30%
[DCF] Terminal Value 81.11% ; FCFF base≈6.68b ; Y1≈6.42b ; Y5≈6.28b
[DCF] Fair Price = 280.9 (EV 135.38b - Net Debt 31.00b = Equity 104.38b / Shares 371.6m; r=7.17% [WACC]; 5y FCF grow -5.31% → 3.0% )
EPS Correlation: -36.29 | EPS CAGR: -47.58% | SUE: -4.0 | # QB: 0
Revenue Correlation: 4.24 | Revenue CAGR: 0.88% | SUE: 3.38 | # QB: 4
EPS next Quarter (2026-06-30): EPS=5.73 | Chg7d=+0.000 | Chg30d=-0.074 | Revisions Net=-2 | Analysts=1
EPS current Year (2026-12-31): EPS=24.86 | Chg7d=+0.237 | Chg30d=+0.380 | Revisions Net=+0 | Growth EPS=+8.7% | Growth Revenue=+7.7%
EPS next Year (2027-12-31): EPS=27.34 | Chg7d=+0.163 | Chg30d=+0.512 | Revisions Net=-2 | Growth EPS=+10.0% | Growth Revenue=+5.7%
[Analyst] Revisions Ratio: -0.50 (1 Up / 3 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.0% (Discount Rate 8.6% - Earnings Yield 3.6%)
[Growth] Growth Spread = +4.0% (Analyst 9.0% - Implied 5.0%)

External Resources

Dataroma Stockcircle